NCT05082545View on ClinicalTrials.gov

Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

July 17, 2023

Study Completion Date

February 12, 2024

Conditions
Advanced Malignant Tumors
Interventions
DRUG

SHR-2002 and SHR-1316

Cohort study

Trial Locations (4)

2031

Scientia Clinical research, Sydney

2170

Liverpool Hospital, Sydney

4101

Icon Cancer Centre, Brisbane

6009

Linear clinical research, Perth

All Listed Sponsors
lead

Atridia Pty Ltd.

INDUSTRY

NCT05082545 - Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors | Biotech Hunter | Biotech Hunter